Previous reports of the RAPID-axSpA trial ( NCT01087762 ) described the efficacy and safety of certolizumab pegol ( CZP ) over 24 weeks in patients with axial spondyloarthritis ( SpA ) , including ankylosing spondylitis ( AS ) and nonradiographic axial SpA .